Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
04/08/2025
The Taiwan Stock Exchange Weighted Index opened 0.7% lower at 23,260.18.
Latest
1 m ago
Financial Report Preview | Data Leader Palantir (PLTR.US) Shows Strong Earning Momentum, Expected Revenue Increase of 38.6% This Quarter Surpassing Peers
2 m ago
Qiawai Food established an agricultural technology company in Hami.
2 m ago
The African swine fever vaccine developed by Hubei Province has been the first to obtain clinical approval.
2 m ago
On July 31st, Guoyao Group's Animal Health Co., Ltd. (hereinafter referred to as "Guoyao Animal Health") received good news: the company was granted the clinical trial approval for the African swine fever vaccine by the Ministry of Agriculture and Rural Affairs, becoming the first enterprise in China to receive this approval. Guoyao Animal Health has always closely monitored the trends of animal diseases at home and abroad, focusing on the research and development of vaccines for diseases such as porcine blue ear disease and porcine circovirus disease, and has previously developed the world's first gene-recombinant strain of porcine blue ear disease live vaccine. In 2021, the company boldly ventured into scientific "no man's land" and established a research and development team for the African swine fever vaccine. Over the past four years, the team has completed multiple research projects on antigen production technology, pilot process research, establishment of semi-finished and finished product testing methods, vaccine stability research, and other scientific research tasks to complete laboratory trials of multiple batches of African swine fever vaccines and research on the safety of the vaccine products (Hubei Daily).
2 m ago
Infineon Technologies rose more than 10%, and the company announced a partnership with Nvidia.
See all latest